The webinars are aimed at decision makers and scouts in the international biotechnology and pharmaceutical industry looking to expand their pipelines in this field. They are free of charge, but registration is necessary.
This is the second webinar to be hosted by Ascenion, following a pilot webinar held in May this year featuring selected…
dentalXrai has been developed by a team around Prof. Falk Schwendicke, Director of the Department of Oral Diagnostics and Digital Dentistry at the Charité, who combined top-notch machine learning and software development know-how with leading dental research expertise to develop a powerful tool that enables the detection of dental pathologies and…
Objects at various distances, can be imaged sharply – without any optical elements moving along the optical axes. Therefore, these proprietary diffractive elements allow the creation of powerful optical systems with reduced size, weight and mechanical complexity. Direct applications include optics for mobile phones, cameras or microscopes,…
In a round table discussion, the translation of scientific ideas into valid projects and commercial assets was highlighted by five companies.
The German Biotechnology Report 2020 was published only in German. Read the interview moderated by S. Bialojan.
The alliance that had been closed in 2015 with the support of Ascenion, aims to develop the company’s unique CAR-CIK technology in combination with the MDC’s proprietary Sleeping Beauty (SB) gene transfer system for the immunotherapy of cancer. The approach has the potential to overcome commercial limitations related to existing CAR-T therapies by…
Munich, 29 April 2020 – Scientists in Hamburg are aiming to improve therapy for HIV patients with a new gene- and cell-based method. At the Hamburg biotech start-up Provirex, they are developing a new therapeutic approach using ‘molecular scissors’ to cut HIV genes out of the genome of infected cells, thus eliminating the virus. This could at last…
Dear clients, partners and technology transfer colleagues,
In these unprecedented and worrying times dominated by the coronavirus pandemic, we remain determined to offer our clients a full service. Your health and that of our colleagues has utmost priority for us. For this reason, we will be avoiding meeting in person until the situation has…
Never full – some people live with a feeling of extreme hunger from birth. The result is obesity, often from early childhood, caused in certain patients by defects in a central molecular signal pathway responsible for maintaining energy balance and triggering a feeling of satiety. Scientists have known for a long time that the melanocortin 4…
T cells are highly potent immune effector cells. Many immunotherapies therefore rely on harnessing them for the destruction of cancer cells. However, tumours often create a hostile microenvironment in order to fight off T cells. They emit checkpoint proteins (such as PD-L1), that diminish or block T-cell activity. Prof. Elfriede Nößner and her…
The agreements were signed in summer 2018. The world’s largest vaccine manufacturer, the Serum Institute of India Pvt. Ltd (SII), has acquired a majority stake in Vakzine Projekt Management GmbH (VPM) in an all-cash transaction. This secures the future of the company and its projects. VPM is a spin-off of the Helmholtz Centre for Infection…
CAR T and CAR NK cell therapies are the current rays of hope for cancer treatment. The patient’s own T cells or NK cells – the immune system’s ‘killer’ cells – are furnished with cancer-specific receptors, allowing them to recognize and specifically destroy cancer cells. Scientists at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin…
The studies were conducted by an international team of scientists from Austria, Germany, Hungary and Great Britain.
The approach is based on the ground-breaking research of Prof. Thomas Thum and his team at the Hannover Medical School. They were the first to demonstrate that increased expression of microRNA 132 (miR132) – a short, non-coding RNA…
At a time when the EC is constructing its goals beyond Horizon 2020 towards Horizon Europe, the meeting was a significant opportunity for the EC to learn from the knowledge transfer community – and for the NAAC to present its proposal on how to increase the impact of European research funding.
The recommendations are:
The introduction of a…
The participants took the opportunity to intensely discuss both important trends in the sector and challenging real-world situations. The high professional level and the trusting atmosphere made the event particularly valuable.
In addition to specialized topics, such as dealing with company investments, due diligence and structuring of agreements…
Under the theme ‘Key Trends in Knowledge Transfer’ the conference will welcome KT’s key influencers as keynote speakers, a wide range of service providers actively supporting KT professionals, and policymakers willing to listen to your experiences.
The best thing to do is to arrive on 27 May in the morning and join the pre-conference program…
Munich, 21 January 2020 - Ascenion’s portfolio company HepaRegeniX has successfully completed a series B financing round in excess of EUR 11 million. All existing investors have contributed: the Boehringer Ingelheim Venture Fund GmbH (BIVF), Novo Holdings A/S, the High-Tech Gruenderfonds, Coparion and Ascenion.
The company will use the proceeds…
Anyone hoping to sell IP to a potential licensee asks themselves this question. This course will show you how to develop well-founded answers, ready for entering into negotiations.
You’ll first get an overview of current standards and common evaluation procedures, then learn more about one of these, the Net Present Value (NPV) method, and try it…
Instead of sending Christmas cards, we have once again decided to support a charity. We will be making a donation to ‘Kleine Riesen’ (‘Little Giants‘), a palliative care team that has been looking after children and adolescents with incurable cancer in Munich since 2005.
We wish you all a merry Christmas, relaxing holidays and every success in…
